Jupiter Neurosciences, Inc. (JUNS) 10-Year Financial Performance & Capital Metrics

JUNS • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutJupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.Show more

Revenue $0
EBITDA -$2M +52.0%
Net Income -$2M +49.0%
EPS (Diluted) -0.08 +39.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -58.48%
ROIC -
Debt/Equity 0.05
Interest Coverage -12.45 +29.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 12.5% through buybacks

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-466.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM-449.77%

ROCE

10Y Avg-73.72%

5Y Avg-73.72%

3Y Avg-73.72%

Latest-73.72%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.13M	638.04K	233.28K	0	0
Revenue Growth %	-	-	-0.43%	-0.63%	-1%	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	1.13M	638.04K	233.28K	0	0
Gross Margin %	-	1%	1%	1%	-	-
Gross Profit Growth %	-	-	-0.43%	-0.63%	-1%	-
Operating Expenses+	2.18M	2.98M	4.55M	3.67M	3.87M	3.09M
OpEx % of Revenue	-	2.64%	7.12%	15.71%	-	-
Selling, General & Admin	1.49M	1.34M	3.1M	2.72M	2.92M	2.6M
SG&A % of Revenue	-	1.19%	4.85%	11.67%	-	-
Research & Development	685.74K	1.64M	1.45M	942.81K	954.79K	492.66K
R&D % of Revenue	-	1.46%	2.27%	4.04%	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-2.18M	-1.85M	-3.91M	-3.43M	-3.87M	-3.09M
Operating Margin %	-	-1.64%	-6.12%	-14.71%	-	-
Operating Income Growth %	-	0.15%	-1.11%	0.12%	-0.13%	0.2%
EBITDA+	-2.73M	-1.64M	-4.09M	-4.22M	-4.56M	-2.19M
EBITDA Margin %	-	-1.46%	-6.4%	-18.08%	-	-
EBITDA Growth %	-	0.4%	-1.49%	-0.03%	-0.08%	0.52%
D&A (Non-Cash Add-back)	0	0	0	0	0	0
EBIT	-2.73M	-1.64M	-4.09M	-4.22M	-4.56M	-2.19M
Net Interest Income+	-317.1K	-13.5K	-113.86K	-740.24K	-218.22K	-242.81K
Interest Income	4	38	132	617	482	5.56K
Interest Expense	317.1K	13.54K	113.99K	740.85K	218.71K	248.37K
Other Income/Expense	-870.06K	196.9K	-293.16K	-1.53M	-912.92K	651.66K
Pretax Income+	-3.05M	-1.65M	-4.2M	-4.96M	-4.78M	-2.44M
Pretax Margin %	-	-1.47%	-6.58%	-21.25%	-	-
Income Tax+	0	0	179.17K	0	0	0
Effective Tax Rate %	1%	1%	1.04%	1%	1%	1%
Net Income+	-3.05M	-1.65M	-4.38M	-4.96M	-4.78M	-2.44M
Net Margin %	-	-1.47%	-6.86%	-21.25%	-	-
Net Income Growth %	-	0.46%	-1.65%	-0.13%	0.04%	0.49%
Net Income (Continuing)	-3.05M	-1.65M	-4.38M	-4.96M	-4.78M	-2.44M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.35	-0.19	-0.44	-0.15	-0.14	-0.08
EPS Growth %	-	0.46%	-1.32%	0.66%	0.07%	0.39%
EPS (Basic)	-0.35	-0.19	-0.44	-0.15	-0.14	-0.08
Diluted Shares Outstanding	8.74M	8.74M	9.49M	32.88M	32.88M	28.78M
Basic Shares Outstanding	8.74M	8.74M	9.49M	32.88M	32.88M	28.78M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.97K	549.98K	454.67K	69.66K	28.74K	4.65M
Cash & Short-Term Investments	1.28K	208K	330.6K	64.43K	28.48K	3.77M
Cash Only	1.28K	208K	330.6K	64.43K	28.48K	3.77M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	126.23K	0	0	0	0
Days Sales Outstanding	-	40.91	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	3.69K	215.75K	124.07K	5.23K	261	114.09K
Total Non-Current Assets+	1.21K	0	212.71K	166.28K	119.85K	1.55M
Property, Plant & Equipment	0	0	208.93K	162.5K	116.07K	69.64K
Fixed Asset Turnover	-	-	3.05x	1.44x	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	500K	0	0	0	0
Other Non-Current Assets	1.21K	-500K	3.78K	3.78K	3.78K	1.48M
Total Assets+	6.18K	549.98K	667.38K	235.94K	148.59K	6.2M
Asset Turnover	-	2.05x	0.96x	0.99x	-	-
Asset Growth %	-	88.04%	0.21%	-0.65%	-0.37%	40.74%
Total Current Liabilities+	5.02M	4.26M	5.68M	7.26M	5.77M	2.01M
Accounts Payable	131.05K	252.19K	256.89K	187.03K	189.5K	278.68K
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	1.21M	108.48K	440.61K	1.73M	2.02M	146.43K
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	3.68M	3.34M	4.53M	4.91M	3.07M	118.87K
Current Ratio	0.00x	0.13x	0.08x	0.01x	0.00x	2.31x
Quick Ratio	0.00x	0.13x	0.08x	0.01x	0.00x	2.31x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	164.4K	119.54K	178.04K	21.25K
Long-Term Debt	0	0	0	0	106.71K	0
Capital Lease Obligations	0	0	164.4K	119.54K	71.33K	21.25K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0
Total Liabilities	5.02M	4.26M	5.85M	7.38M	5.95M	2.03M
Total Debt+	1.21M	108.48K	651.2K	1.9M	2.25M	217.76K
Net Debt	1.21M	-99.52K	320.6K	1.83M	2.22M	-3.55M
Debt / Equity	-	-	-	-	-	0.05x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-6.86x	-136.80x	-34.27x	-4.63x	-17.70x	-12.45x
Total Equity+	-5.02M	-3.71M	-5.18M	-7.14M	-5.8M	4.17M
Equity Growth %	-	0.26%	-0.4%	-0.38%	0.19%	1.72%
Book Value per Share	-0.57	-0.42	-0.55	-0.22	-0.18	0.14
Total Shareholders' Equity	-5.02M	-3.71M	-5.18M	-7.14M	-5.8M	4.17M
Common Stock	553	627	653	2.64K	2.65K	3.31K
Retained Earnings	-7.99M	-9.64M	-13.84M	-18.8M	-23.58M	-26.02M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-142.95K	-254.78K	-1.74M	-1.25M	-480.95K	-3.91M
Operating CF Margin %	-	-0.23%	-2.72%	-5.35%	-	-
Operating CF Growth %	-	-0.78%	-5.81%	0.28%	0.61%	-7.13%
Net Income	-3.05M	-1.65M	-4.2M	-4.96M	-4.78M	-2.44M
Depreciation & Amortization	0	0	0	0	0	0
Stock-Based Compensation	944.58K	563.53K	1.3M	817.25K	1.2M	1.84M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	865.63K	-127.74K	381.43K	1.34M	755.91K	-746.57K
Working Capital Changes	1.09M	964.13K	781.29K	1.55M	2.35M	-2.57M
Change in Receivables	0	-126.23K	126.23K	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	162.73K	185.96K	-155.26K	-56.28K	164.88K	-149.53K
Cash from Investing+	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	0%	0%	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	107.79K	461.5K	1.86M	982.33K	445K	7.65M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	107.79K	500K	500K	0	0	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-142.95K	-254.78K	-1.74M	-1.25M	-480.95K	-3.91M
FCF Margin %	-	-0.23%	-2.72%	-5.35%	-	-
FCF Growth %	-	-0.78%	-5.81%	0.28%	0.61%	-7.13%
FCF per Share	-0.02	-0.03	-0.18	-0.04	-0.01	-0.14
FCF Conversion (FCF/Net Income)	0.05x	0.15x	0.40x	0.25x	0.10x	1.60x
Interest Paid	0	0	1.06K	81.5K	28.13K	147.78K
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-58.48%
Gross Margin	-	100%	100%	100%	-	-
Net Margin	-	-146.92%	-686.39%	-2125.15%	-	-
Debt / Equity	-	-	-	-	-	0.05x
Interest Coverage	-6.86x	-136.80x	-34.27x	-4.63x	-17.70x	-12.45x
FCF Conversion	0.05x	0.15x	0.40x	0.25x	0.10x	1.60x
Revenue Growth	-	-	-43.35%	-63.44%	-100%	-

Frequently Asked Questions

Growth & Financials

Jupiter Neurosciences, Inc. (JUNS) grew revenue by 0.0% over the past year. Growth has been modest.

Jupiter Neurosciences, Inc. (JUNS) reported a net loss of $7.6M for fiscal year 2024.

Dividend & Returns

Jupiter Neurosciences, Inc. (JUNS) has a return on equity (ROE) of -58.5%. Negative ROE indicates the company is unprofitable.

Jupiter Neurosciences, Inc. (JUNS) had negative free cash flow of $6.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener